Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron: Time For Biopharma To Step Up, Support Budding Scientists

Executive Summary

Concerned that Americans are no longer revering science the way the country did 50 years ago, Regeneron Pharmaceuticals Inc. leaders Leonard Schleifer and George Yancopoulos decided it was time for the biopharmaceutical industry to do more than just talk the talk in urging youngsters to pursue science, technology, engineering and math careers and have stepped up with a $100m pledge to sponsor the nation's top high school competition – the Science Talent Search.

You may also be interested in...



More Women Scientists Needed, Obama Demands

President Barack Obama on April 13 called for ensuring there's more opportunities for women in the fields of science, technology, engineering and math (STEM).

This is what genius looks like

Budding scientists, some as young as five years old, invaded the White House on 23 March, bringing with them their very atypical science fair projects, with some involving novel ways to discover and develop drugs and diagnostics.

Teens' cancer, flu treatment discoveries catch industry attention

Biopharmaceutical and other companies already are lining up to help bring discoveries to the marketplace from some innovative American teenagers, whose experiments in cancer and influenza drug development were on display at President Barack Obama's fourth annual White House Science Fair on 27 May.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel